Predictors of high residual gradient after transcatheter aortic valve replacement in bicuspid aortic valve stenosis.


Journal

Clinical research in cardiology : official journal of the German Cardiac Society
ISSN: 1861-0692
Titre abrégé: Clin Res Cardiol
Pays: Germany
ID NLM: 101264123

Informations de publication

Date de publication:
May 2021
Historique:
received: 20 08 2020
accepted: 09 12 2020
pubmed: 4 1 2021
medline: 20 11 2021
entrez: 3 1 2021
Statut: ppublish

Résumé

To define the incidence of high residual gradient (HRG) after transcatheter aortic valve replacement (TAVR) in BAVs and their impact on short term outcome and 1-year mortality. Transcatheter heart valves (THVs) offer good performance in tricuspid aortic valves with low rate of HRG. However, data regarding their performance in bicuspid aortic valves (BAV) are still lacking. The BEAT (Balloon vs Self-Expandable valve for the treatment of bicuspid Aortic valve sTenosis) registry included 353 consecutive patients who underwent TAVR (Evolut R/PRO or Sapien 3 valves) in BAV between June 2013 and October 2018. The primary endpoint was device unsuccess with post-procedural HRG (mean gradient ≥ 20 mmHg). The secondary endpoint was to identify the predictors of HRG following the procedure. Twenty patients (5.6%) showed HRG after TAVR. Patients with HRG presented higher body mass index (BMI) (30.7 ± 9.3 vs. 25.9 ± 4.8; p < 0.0001) and higher baseline aortic mean gradients (57.6 ± 13.4 mmHg vs. 47.7 ± 16.6, p = 0.013) and more often presented with BAV of Sievers type 0 than patients without HRG. At multivariate analysis, BMI [odds ratio (OR) 1.12; 95% confidence interval (CI) 1.05-1.20, p = 0.001] and BAV type 0 (OR 11.31, 95% CI 3.45-37.06, p < 0.0001) were confirmed as independent predictors of high gradient. HRG following TAVR in BAVs is not negligible and is higher among patients with high BMI and with BAV 0 anatomy.

Sections du résumé

OBJECTIVES OBJECTIVE
To define the incidence of high residual gradient (HRG) after transcatheter aortic valve replacement (TAVR) in BAVs and their impact on short term outcome and 1-year mortality.
BACKGROUND BACKGROUND
Transcatheter heart valves (THVs) offer good performance in tricuspid aortic valves with low rate of HRG. However, data regarding their performance in bicuspid aortic valves (BAV) are still lacking.
METHODS METHODS
The BEAT (Balloon vs Self-Expandable valve for the treatment of bicuspid Aortic valve sTenosis) registry included 353 consecutive patients who underwent TAVR (Evolut R/PRO or Sapien 3 valves) in BAV between June 2013 and October 2018. The primary endpoint was device unsuccess with post-procedural HRG (mean gradient ≥ 20 mmHg). The secondary endpoint was to identify the predictors of HRG following the procedure.
RESULTS RESULTS
Twenty patients (5.6%) showed HRG after TAVR. Patients with HRG presented higher body mass index (BMI) (30.7 ± 9.3 vs. 25.9 ± 4.8; p < 0.0001) and higher baseline aortic mean gradients (57.6 ± 13.4 mmHg vs. 47.7 ± 16.6, p = 0.013) and more often presented with BAV of Sievers type 0 than patients without HRG. At multivariate analysis, BMI [odds ratio (OR) 1.12; 95% confidence interval (CI) 1.05-1.20, p = 0.001] and BAV type 0 (OR 11.31, 95% CI 3.45-37.06, p < 0.0001) were confirmed as independent predictors of high gradient.
CONCLUSION CONCLUSIONS
HRG following TAVR in BAVs is not negligible and is higher among patients with high BMI and with BAV 0 anatomy.

Identifiants

pubmed: 33389062
doi: 10.1007/s00392-020-01793-9
pii: 10.1007/s00392-020-01793-9
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

667-675

Commentaires et corrections

Type : ErratumIn

Références

Mack MJ, Leon MB, Thourani VH et al (2019) Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med 380(18):1695–1705
doi: 10.1056/NEJMoa1814052
Leon MB, Smith CR, Mack MJ et al (2016) Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med 374:1609–1620
doi: 10.1056/NEJMoa1514616
Leon MB, Smith CR, Mack M et al (2010) Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 363(17):1597–1607
doi: 10.1056/NEJMoa1008232
Kawamori H, Yoon SH, Chakravarty T et al (2018) Computed tomography characteristics of the aortic valve and the geometry of SAPIEN 3 transcatheter heart valve in patients with bicuspid aortic valve disease. Eur Heart J Cardiovasc Imaging 19(12):1408–1418
doi: 10.1093/ehjci/jex333
Sievers HH, Schmidtke C (2007) A classification system for the bicuspid aortic valve from 304 surgical specimens. J ThoracCardiovascSurg 133(5):1226–1233
Kappetein AP, Head SJ, Généreux P et al (2012) Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. Eur Heart J 33(19):2403–2418
doi: 10.1093/eurheartj/ehs255
Kappetein AP, Head SJ, Généreux P et al (2013) Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J ThoracCardiovascSurg 145(1):6–23
Mangieri A, Chieffo A, Won-Keun W et al (2018) Transcatheter aortic valve implantation using the ACURATE neo in bicuspid and tricuspid aortic valve stenosis: a propensity-matched analysis of a European experience. EuroIntervention 14(12):e1269–e1275
doi: 10.4244/EIJ-D-18-00281
Halim SA, Edwards FH, Dai D et al (2020) Outcomes of transcatheter aortic valve replacement in patients with bicuspid aortic valve disease: a report from the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. Circulation 141(13):1071–1079
doi: 10.1161/CIRCULATIONAHA.119.040333
Del Trigo M, Muñoz-Garcia AJ, Wijeysundera HCM et al (2016) Incidence, timing, and predictors of valve hemodynamic deterioration after transcatheter aortic valve replacement multicenter registry. J Am Coll Cardiol 67(6):644–655
doi: 10.1016/j.jacc.2015.10.097
Yousef A, Simard T, Webb JA et al (2015) Transcatheter aortic valve implantation in patients with bicuspid aortic valve: a patient level multi-center analysis. Int J Cardiol 189:282–288
doi: 10.1016/j.ijcard.2015.04.066
Yoon SH, Bleiziffer S, De Backer O et al (2017) Outcomes in transcatheter aortic valve replacement for bicuspid versus tricuspid aortic valve stenosis. J Am Coll Cardiol 69(21):2579–2589
doi: 10.1016/j.jacc.2017.03.017
Freitas-Ferraz AB, Tirado-Conte G, Dagenais F et al (2019) Aortic stenosis and small aortic annulus. Circulation 139(23):2685–2702
doi: 10.1161/CIRCULATIONAHA.118.038408
Miyasaka M, Tada N, Taguri M, OCEAN-TAVI Investigators et al (2018) Incidence, predictors, and clinical impact of prosthesis-patient mismatch following transcatheter aortic valve replacement in asian patients: the OCEAN-TAVI registry. J Am Coll CardiolIntv 11(8):771–780
doi: 10.1016/j.jcin.2018.01.273
Fallon JM, DeSimone JP, Brennan JM et al (2018) The incidence and consequence of prosthesis-patient mismatch after surgical aortic valve replacement. Ann ThoracSurg 106(1):14–22
doi: 10.1016/j.athoracsur.2018.01.090
Martin C, Sun W (2017) Transcatheter valve underexpansion limits leaflet durability: implications for valve-in-valve procedures. Ann Biomed Eng 45(2):394–404
doi: 10.1007/s10439-016-1738-8

Auteurs

Giulia Bugani (G)

Cardiology Unit, Azienda Ospedaliero Universitaria di Ferrara Arcispedale Sant'Anna, Ferrara, Italy.

Matteo Pagnesi (M)

San Raffaele Scientific Institute, Milan, Italy.

Didier Tchetchè (D)

Groupe CardioVasculaire Interventionnel, Clinique Pasteur, Toulouse, France.

Won- Keun Kim (WK)

Department of Cardiology, Kerckhoff Heart Center, Bad Nauheim, Germany.

Arif Khokhar (A)

Interventional Cardiology Unit, GVM Care and Research, Maria Cecilia Hospital, via della Corriera 1, 48033, Cotignola, Ravenna, Italy.

Jean- Malte Sinning (JM)

Cardiology Department, University Hospital Bonn, Bonn, Germany.

Uri Landes (U)

Cardiology Department, Rabin Medical Center, Petah Tikva, Israel.

Ran Kornowski (R)

Cardiology Department, Rabin Medical Center, Petah Tikva, Israel.

Pablo Codner (P)

Cardiology Department, Rabin Medical Center, Petah Tikva, Israel.

Ole De Backer (O)

The Heart Center-Rigshospitalet, Copenhagen, Denmark.

Georg Nickenig (G)

Cardiology Department, University Hospital Bonn, Bonn, Germany.

Alfonso Ielasi (A)

Istituto Clinico Sant'Ambrogio, Milan, Italy.

Chiara De Biase (C)

Groupe CardioVasculaire Interventionnel, Clinique Pasteur, Toulouse, France.

Lars Søndergaard (L)

The Heart Center-Rigshospitalet, Copenhagen, Denmark.

Federico De Marco (F)

Department of Cardiology, IRCCS Policlinico San Donato, Milan, Italy.

Marco Ancona (M)

San Raffaele Scientific Institute, Milan, Italy.

Matteo Montorfano (M)

San Raffaele Scientific Institute, Milan, Italy.

Damiano Regazzoli (D)

Clinical and Interventional Cardiology Unit, Cardio Center, Humanitas Research Hospital, Rozzano, Milan, Italy.

Giulio Stefanini (G)

Clinical and Interventional Cardiology Unit, Cardio Center, Humanitas Research Hospital, Rozzano, Milan, Italy.

Stefan Toggweiler (S)

Heart Center Lucerne, Luzerner Kantonsspital, Lucerne, Switzerland.

Corrado Tamburino (C)

Cardiology Division, CAST Policlinico Hospital, University of Catania, Catania, Italy.

Sebastiano Immè (S)

Centro Cuore Morgagni, Catania, Italy.

Giuseppe Tarantini (G)

Interventional Cardiology Unit, University of Padova, Padua, Italy.

Horst Sievert (H)

Cardiovascular Center Frankfurt, Frankfurt, Germany.
Anglia Ruskin University, Chelmsford, UK.

Ulrich Schäfer (U)

UKE Hamburg, Hamburg, Germany.

Jörg Kempfert (J)

Deutsches Herzzentrum Berlin, Charité Universitätsmedizin, Berlin, Germany.

Jochen Wöehrle (J)

Ulm University, Ulm, Germany.

Maurizio Tespili (M)

Istituto Clinico Sant'Ambrogio, Milan, Italy.

Alessandra Laricchia (A)

Interventional Cardiology Unit, GVM Care and Research, Maria Cecilia Hospital, via della Corriera 1, 48033, Cotignola, Ravenna, Italy.

Azeem Latib (A)

Department of Cardiology, Montefiore Medical Center, New York, NY, USA.
Division of Cardiology, Department of Medicine, University of Cape Town, Cape Town, South Africa.

Francesco Giannini (F)

Interventional Cardiology Unit, GVM Care and Research, Maria Cecilia Hospital, via della Corriera 1, 48033, Cotignola, Ravenna, Italy.

Antonio Colombo (A)

Interventional Cardiology Unit, GVM Care and Research, Maria Cecilia Hospital, via della Corriera 1, 48033, Cotignola, Ravenna, Italy.
EMO GVM Centro Cuore Columbus, Milan, Italy.

Antonio Mangieri (A)

Interventional Cardiology Unit, GVM Care and Research, Maria Cecilia Hospital, via della Corriera 1, 48033, Cotignola, Ravenna, Italy. antonio.mangieri@gmail.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH